Login to Your Account



AAN 2015

Surrogate biomarkers are gaining in interest but development path is still foggy

By Marie Powers
News Editor

Thursday, April 23, 2015
WASHINGTON – The FDA has been under the gun to qualify more biomarkers that could help accelerate the development of targeted therapies and track the progression of various diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription